Reply to 'Revisiting signatures of neutral tumor evolution in the light of complexity of cancer genomic data' Williams et al. reply -Balaparya and De 1 question the applicability of the power-law neutral-evolution model to adequately describe the pattern of subclonal somatic mutations in bulk cancer sequencing data.
The authors' letter focuses on the issues of the inherent noise in next-generation sequencing data, whereby random sampling of alleles, PCR amplification during library preparation, limited depth sequencing, and subclonal copy number changes may cause considerable uncertainty in variantallele frequency (VAF) measurement. The authors suggest that these errors lead to VAF measurements that, owing to overdispersion, follow a beta-binomial and not a binomial distribution. We thank Balaparya and De for the insightful comments and address their points in the response below.
The issue of VAF measurement accuracy is a very important point and something that concerned us in our original study 2 . For this reason, we provided extensive error-propagation analysis in our original manuscript to identify the inherent biases that affect VAF estimation (Methods and equations (12)-(14) in ref. 2 ). We aimed at starting from the analytical form of neutral evolution (equation (7) in ref.
2 ) as the expected signal (S) and adding the different sources of noise (N), such as purity and allele sampling during library preparation, to generate the expected pattern S + N reported by the data. Our results demonstrate that the signature of neutral evolution is detectable with moderately high sequencing depth (≥ 100× ; Methods and Supplementary Fig. 10 in ref. 2 ), and we fully acknowledged that the signature of neutral evolution versus selection cannot be reasonably extracted (or rejected) from lower-depth datasets.
In an effort to address Balaparya and De's concerns, we tested the ability of our model to recover neutral evolutionary dynamics in the presence of beta-binomially distributed noise, and we found no significant differences with respect to the binomial noise used in our original manuscript, although with very high dispersion (ρ = 0.1), a degree of difference was appreciable (Fig. 1a) . Moreover, we estimated the degree of overdispersion in the data that we analyzed in ref. 2 by fitting a beta-binomial model to the clonal cluster by using Markovchain Monte Carlo inference. In both the 100× whole-genome gastric cancer 3 and whole-exome colon cancer 4 data, we estimated the dispersion parameter ρ to be < 0.005 (Fig. 1b,c, respectively) , a value notably 10× lower than postulated by Balaparya and De (Fig. 1c,d in ref. 1 ). Given that as ρ→ 0, the beta-binomial distribution converges to a binomial distribution, we argue that using a binomial distribution to model noise in sequencing data was appropriate in our original analysis.
Balaparya and De also suggest that, because copy number alterations affect VAF distributions, very strict thresholds are necessary to ensure that regions analyzed with our method are truly diploid. This is an important point, and we concur that the original threshold of absolute log R ratio ≤ 0.5 may have been too lenient. To test the effect of this confounding factor, we reanalyzed the TCGA pan-cancer dataset by using the new publicly accessible Genomic Data Commons Data Portal (see URLs) variant calls, which were not available at the time of our original manuscript. We downloaded data from 8,455 TCGA tumors of different cancer types and selected cancers with high purity (≥ 70%) by using variants called with Mutect2, as we did in our original manuscript. We then adjusted the VAF for the purity obtained from ref. 5 and identified diploid regions by using absolute copy number calls from ref. 6 . We then classified tumors as neutral/ non-neutral, by using mutations in regions with copy number n = 2. We used the allele frequency f = [0.12, 0.24] integration range and required a minimum of 12 subclonal mutations, as in our original manuscript. Out of the 8,455 tumors, 724 satisfied all the conditions (reasons for exclusion in Supplementary Fig. 1 ). This analysis confirmed our original findings with a similarly large proportion of tumors classified as neutral: 40% of neutral cases were identified in this cohort (290/724), compared with 31% in our original analysis (Supplementary Table 1 ). Hence, these confounding factors are more likely to lead to incorrect rejection of the neutral model rather than incorrect acceptance. In terms of copy number alterations, this conclusion makes sense, because they would generate binomial clusters in the VAF distribution that would erroneously appear as subclonal clusters.
Therefore, although Balaparya and De provide a perfectly reasonable critique, the ). We consider this alternative explanation highly unlikely. Although we agree with the authors that we cannot exclude that specific combinations of parameters from specific distributions might also fit the 1/f cumulative distribution, there are problems with the biological interpretation of low-frequency betabinomially distributed subclonal clusters as a sole alternative explanation. Specifically, the number of mutations that we detect in the 1/f tail is consistently very large, almost always larger than the number of mutations in the clonal cluster. This relationship makes sense in terms of neutral evolution, because these mutations accumulate naturally in different lineages at the same time. According to the authors' proposition, instead, in 30% of cases, there would be an extremely old subclone (containing a large number of variants), possibly older than the time between the patient's birth and cancer initiation (because the subclonal cluster contains more mutations than the clonal cluster). Additionally, this very old subclone would always be partially hidden from sight because of its low frequency, showing only the right-hand tail of its distribution but never presenting itself in full (Fig. 1c  in ref.   1 ). We argue that this interpretation of the data is rather implausible, and more importantly, it is in conflict with the body of evidence from tumor phylogenetic trees that consistently show a long trunk and shorter diversification branches. Therefore, although we cannot definitively exclude this alternative explanation on the basis of the observed power-law distribution alone, we argue that the alternative explanation is an artificial construction that immediately implies many implausible consequences. Furthermore, we note that in a recent study led by colleagues 7 , when we leveraged on multiregion sequencing of colorectal cancer to analyze neutral tails in exome data, we demonstrated that those tails describe mutations that are not in the same cells, and hence that 1/f tails are not subclones (Fig. 4 in ref. 
7
). Balaparya and De suggest further alternative explanations for a 1/f tail ( Fig. 1d-f in ref. 1 ) These simulated examples show how a specifically chosen mixture of two or three subclones produces a similar 1/f pattern in the cumulative distribution and suggest that such mixtures may confound our calling of neutrality. Although we cannot exclude that any specific mixture of subclones might by chance present a signature that is similar to the null model, it seems extremely unlikely that such a 'perfect mixture' of subclones exists in > 30% of all tumors, especially because the frequency and number of mutations in these clones must be within a very tight range (in the example shown by Balaparya and De and colleagues, there are precisely 1,000 mutations in each clone, and the dispersions are also very specific). From a phenomenological perspective, for a clonal mixture to appear neutral-like would require both the time of appearance of a new subclone (which sets the number of mutations in the subclone) and its selective advantage (which defines the size of the subclone at the time the tumor is sampled) 7 to be 'just right' . This fine-tuning is exacerbated as more subclones are introduced.
We would like to stress that our analysis is built from first principles: we constructed a dynamical model of tumor growth that incorporates the fundamental mechanisms of cell division and mutation, and we do not make assumptions regarding how clonal mixtures should look. We argue that Balaparya and De's synthetic examples are not based on a model of tumor evolution. In particular, their subclones are isogenic, and mutation frequencies are normalized; hence, we argue that neutrality is a more parsimonious and much more likely explanation of the available data.
Balaparya and De also report that TCGA tumors classified as neutral with our method were classified as polyclonal (two to eight subclones) with other methods 8 . However, the authors do not mention which specific cases they refer to, nor do they present their VAF distribution for examination; hence, we are unable address this point. We note, however, that further work has shown that neutral tails can be mistaken for subclones 7 ; therefore, it is unsurprising that previous clustering methods are biased , we generated 1,000 in silico tumors and then subjected the same 1,000 simulations to different sampling regimes to generate synthetic datasets. From these synthetic datasets, we calculated R 2 values by fitting the neutral model. a, As the degree of dispersion increases (increased ρ) the mean R 2 becomes lower. However, using our cutoff of 0.98, we would still correctly classify 86% of samples as neutral even in the most extreme case of over-dispersion (ρ = 0.1) compared with 92% by using binomial sampling. b,c, Using Markov-chain Monte Carlo to fit a beta-binomial model to the clonal cluster on our data, we demonstrate that the dispersion is ρ < 0.005 (ten times lower than proposed by Balaparya and De) in both our whole-genome-sequencing gastric cancer cohort and whole-exome-sequencing colon cancer cohort. The beta-binomial distribution becomes a binomial distribution for ρ→ 0. Because we consistently find low ρ in our cancer genomic data, we argue that binomial sampling and beta-binomial sampling converge. toward overclustering. We do acknowledge that the 1/f analytical test is sensitive to the integration range, and this is why we have been developing new methods that instead use the whole VAF distribution 9 . Overall, we maintain that if the data are adequately described by the null model of what we expect in the absence of selection, then according to Occam's razor, we would need additional strong evidence for selection to incorporate additional complexity into our explanations of the available data. As we collect higher-resolution data, we may later be able to reject the null hypothesis.
We wholly agree with the authors' point that the limited depth of sequencing data restricts the resolvability of 'microscopic' evolutionary dynamics, and we have discussed this in ref. , our analysis connects time with the allelic-frequency spectrum so that only the earliest branches of the evolutionary process are observable via bulk sequencing at the current usually moderate depth. The deeper the sequencing, the more recent evolutionary events we can observe. Therefore, most of what we can observe with current bulk sequencing occurred early in tumor development, and microevolution, as also stated by the authors, cannot be observed with current standards. This caveat, however, does not invalidate our analysis but instead provides information on the level of accuracy at which we can understand tumor evolution with current sequencing data. We entirely agree that potentially variable microevolution occurs in tumors at a scale that is currently undetectable in the data, and we maintain that to study microevolution, multiregion sequencing 10 is likely to be the only solution. This is the reason why, in follow-up studies, we did extend our approach to multiregion profiling 7 . Importantly, the salient point that we would like to convey from our previous study 2 is that in many cancers, neutral evolution-the most parsimonious description of the evolutionary process of cancer growth-is an adequate description of the available sequencing data.
In conclusion, we thank Balaparya and De for providing constructive criticism that has led to important new analyses and improvement of our methods. All these new analyses indicate that neutral evolution seems to play an important role in cancer and, although selection remains the critical force that leads to adaptation, neutrality is fundamental to the understanding of how genomic alterations accumulate in a growing tumor within and between selected subpopulations.
URLs. Genomic Data Commons Data Portal, https://portal.gdc.cancer.gov/.
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Gastric cancers from ref. 3 and colorectal cancers from ref. 4 were analyzed with our framework in our original manuscript Neutral tumor evolution?
To the Editor -Tumor growth is an evolutionary process that is governed by somatic mutation, clonal selection and random genetic drift, and is constrained by the coevolution of the microenvironment 1, 2 . Tumor subclones are subpopulations of tumor cells with a common set of mutations resulting from the expansion of a single cell during tumor development, and they have been observed in a substantial fraction of cancers and across multiple cancer types 3 .
Peter Nowell has proposed that tumors evolve through sequential genetic events 4 , whereby one cell acquires a selective advantage so that its lineage becomes predominant. According to this traditional model, the selective advantage is conferred by a small set of driver mutations, but as the subclones that bear them successively expand, they also accumulate passenger mutations, which can be detected in sequencing experiments 1 . Genomes of individual tumors contain hundreds to many thousands of these genetic variants at a wide range of frequencies 5, 6 . Because genetic drift can drive novel variants to high frequencies, it is of great interest to discern the relative importance of selection and drift in shaping the frequency distribution of variants in any given tumor.
Williams et al. 7 have recently proposed a way to assess this relative importance. They have found that a simple model of
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For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Figure 1C) were analyzed with our framework in our original manuscript. The new TCGA pan-cancer analysis is based on publicly available GDC calls that can be downloaded from https://portal.gdc.cancer.gov/ (see Table S1 ).
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